Headlines about OvaScience (NASDAQ:OVAS) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OvaScience earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.4295259170816 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

A number of research firms have weighed in on OVAS. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of OvaScience in a research note on Monday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of OvaScience in a research note on Thursday, August 3rd. Finally, Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Wednesday, October 4th.

OvaScience (NASDAQ:OVAS) remained flat at $$1.50 during mid-day trading on Tuesday. The company’s stock had a trading volume of 213,590 shares, compared to its average volume of 237,521. OvaScience has a twelve month low of $1.25 and a twelve month high of $4.20.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/07/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-ovascience-ovas-stock-price.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Stock Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related stocks with our FREE daily email newsletter.